Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Encysive Thelin pivotal trial

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Encysive plans to submit an NDA for Thelin (sitaxsentan) for pulmonary arterial hypertension "on or around the end of the first quarter in 2005." The company, formerly Texas Biotech, announced enrollment was complete for the Phase III Sitaxsentan To Relieve ImpaireD Exercise (STRIDE-2) study Sept. 8. The 240-patient, 18-week, double-blind, placebo-controlled trial includes a "third party bosentan [Actelion's Tracleer] arm," Encysive says. Topline data are expected in February 2005. The confirmatory trial is being conducted under FDA's special protocol assessment program (1Pharmaceutical Approvals Monthly Sept. 1, 2003, p. 17)...

You may also be interested in...

Encysive Thelin PAH submission

Encysive submits its oral endothelin receptor antagonist Thelin (sitaxsentan) for treatment of pulmonary arterial hypertension, the firm announces May 25. The NDA "contains the largest database ever assembled in a regulatory filing for PAH, with approximately 900 PAH patients receiving Thelin," the Houston-based company said. The NDA includes two pivotal trials, the second of which (STRIDE-2) was conducted under a special protocol assessment with FDA (1Pharmaceutical Approvals Monthly September 2004, In Brief). Thelin would be entering an increasingly competitive market: CoTherix' inhaled prostacyclin Ventavis (iloprost) cleared FDA last December (2Pharmaceutical Approvals Monthly January 2005, p. 3) and Pfizer's Revatio (sildenafil) cleared FDA June 3 (see related brief, p. 15)...

Special Protocol Assessment Requests Up 10%-15% Over FY2002

Sponsor requests for special protocol assessments continue to rise with a 10% to 15% increase so far in 2003, according to FDA.

Washington State Ecology Mulls ‘Safer’ Definition While Exploring Phthalate Alternatives In Fragrances

Marissa Smith, senior regulatory toxicologist in the Washington Department of Ecology’s Hazardous Waste and Toxics Reduction program, discusses what’s next for the state’s inaugural Safer Products go-round. “How we define ‘safer’ is really going to be the lynchpin of this whole process,” she says.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts